Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | LPO | P22079 | 1/20 | 0.31 |
| ▸ | INMT | O95050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13061921 | 0.76 | BRD9 (0.43) | CYP2A6 | |
| SCHEMBL22215584 | 0.76 | CYP2A6 (0.32) | CYP2A6 | |
| SCHEMBL22796965 | 0.76 | KDM4E (0.43) | CYP2A6 | |
| SCHEMBL22166994 | 0.76 | PDE4B (0.30) | CYP2A6 | |
| SCHEMBL18418923 | 0.76 | CYP2A6 (0.30) | CYP2A6 | |
| SCHEMBL18464511 | 0.73 | PDE7A (0.31) | — | |
| SCHEMBL24653241 | 0.73 | — | — | |
| SCHEMBL21594783 | 0.71 | PDE7A (0.33) | — | |
| SCHEMBL17933520 | 0.70 | — | — | |
| SCHEMBL24225308 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022087475-A1 | REVERSE TRANSCRIPTION OF POLYNUCLEOTIDES COMPRISING UNNATURAL NUCLEOTIDES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-04-28 | — | — | WO | disclosed |
| EP-3943607-A1 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | The Scripps Research Institute (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20210222147-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | SANOFI (FR) | 2021-07-22 | — | — | US | disclosed |
| WO-2021072167-A1 | COMPOSITIONS AND METHODS FOR IN VIVO SYNTHESIS OF UNNATURAL POLYPEPTIDES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021067313-A1 | EUKARYOTIC SEMI-SYNTHETIC ORGANISMS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2020256639-A1 | AN APTAMER FOR DENGUE VIRUS AND RELATED METHODS AND PRODUCTS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020252262-A1 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020163532-A1 | IL-2 CONJUGATES AND METHODS OF USE THEREOF | Synthorx, Inc. (US) | 2020-08-13 | — | — | WO | disclosed |
| EP-3656781-A1 | A METHOD FOR THE SITE-SPECIFIC ENZYMATIC LABELLING OF NUCLEIC ACIDS IN VITRO BY INCORPORATION OF UNNATURAL NUCLEOTIDES | The Scripps Research Institute (US) | 2020-05-27 | — | — | EP | disclosed |
| US-20200095591-A1 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | THE SCRIPPS RESEARCH INSTITUTE | 2020-03-26 | — | — | US | disclosed |
| US-10513706-B2 | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-12-24 | — | — | US | disclosed |
| WO-2019014267-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. (US) | 2019-01-17 | — | — | WO | disclosed |
| US-20170029829-A1 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-02-02 | — | — | US | disclosed |
| US-20160168187-A1 | A METHOD FOR THE SITE-SPECIFIC ENZYMATIC LABELLING OF NUCLEIC ACIDS IN VITRO BY INCORPORATION OF UNNATURAL NUCLEOTIDES | Synthorx, Inc. (US) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200095591-A1 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | NUDT1, UPP1, UMPS | CYP2A6 4072/4885SLC6A2 326/4885SLC6A4 698/4885 |
| US-20160168187-A1 | A METHOD FOR THE SITE-SPECIFIC ENZYMATIC LABELLING OF NUCLEIC ACIDS IN VITRO BY INCORPORATION OF UNNATURAL NUCLEOTIDES | RNGTT, POLM, POLRMT | CYP2A6 3111/4885SLC6A2 2221/4885SLC6A4 2305/4885 |
| US-20170029829-A1 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | NUDT1, UPP1, UMPS | CYP2A6 4072/4885SLC6A2 326/4885SLC6A4 698/4885 |
| US-10513706-B2 | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters | NUDT1, UPP1, UMPS | CYP2A6 4072/4885SLC6A2 326/4885SLC6A4 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.